Mankind Pharma partners with Denovo Sciences to drive AI-led innovation in drug discovery

image credit- freepik

Mankind Pharma has announced a strategic collaboration with Armenia-based Denovo Sciences to launch an AI-led drug discovery programme, marking an important step in the company’s focus on innovation-driven and technology-enabled research and development.

The partnership will bring together Mankind Pharma’s strong R&D capabilities, experimental validation infrastructure, and clinical development expertise with Denovo Sciences’ proprietary platform for AI-driven molecular generation and prioritisation.

Together, both organisations will work under a human-in-the-loop model, where AI generates and evaluates molecular candidates while scientific experts guide, validate, and refine the results at every stage.

The collaboration is focused on three key goals: reducing early drug discovery timelines, improving the quality of lead candidates, and ensuring that only candidates with the strongest development potential move ahead. By using computational precision in the early stages of discovery, both partners aim to reduce the time and resources spent on candidates that may not succeed later. The long-term goal, as highlighted by both organisations, is to benefit patients. Faster discovery cycles and better candidate selection can help bring differentiated, effective, and accessible therapies to patients sooner.

For Mankind Pharma, this collaboration reflects a clear move beyond traditional drug discovery methods. The company has been expanding its R&D ambitions in recent years, and the partnership with Denovo Sciences represents its strongest step yet towards using AI as a core tool in the drug development process.